Trials / Completed
CompletedNCT00461136
Time Course of the Antiproteinuric and Blood Pressure Lowering Effects After Initiation of Renin Inhibition With Aliskiren in Type 2 Diabetes
An Open-label, One-period, One-treatment Study to Evaluate the Time Course of the Antiproteinuric and Blood Pressure Lowering Effects After Initiation of Renin Inhibition With Aliskiren in Type 2 Diabetes Suffering From Incipient and/or Established Nephropathy
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 18 (planned)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 30 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the time-course of the antiproteinuric effect of renin inhibition with Aliskiren in patients with Type 2 diabetes suffering from incipient and/or established nephropathy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Aliskiren |
Timeline
- Start date
- 2005-08-01
- Primary completion
- 2006-11-01
- Completion
- 2006-11-01
- First posted
- 2007-04-17
- Last updated
- 2016-09-23
Locations
1 site across 1 country: Denmark
Source: ClinicalTrials.gov record NCT00461136. Inclusion in this directory is not an endorsement.